早期白蛋白输注与脓毒症/脓毒性休克合并重度急性肾损伤患者出院生存率提高相关
该回顾性队列研究利用Cerner Health Facts国家数据库,纳入2013年1月至2018年4月因脓毒症/脓毒性休克住院并发生3期急性肾损伤的成人患者(n=2,829,共2,845次唯一住院记录)。按白蛋白暴露时机分为早期白蛋白组(入院≤24小时内)与非早期组(未暴露或延迟暴露),采用病因别风险模型分析早期白蛋白与临床稳定出院率的关系。结果显示仅8.6%病例早期使用白蛋白;早期组中位出院时间13.2天,非早期组17.0天(Log-rank p<0.0001);校正后早期组临床稳定出院率较非早期组提高83%(HR 1.832,95%CI 1.564-2.146,p<0.001)。作者认为早期白蛋白可能改善此类患者的医疗资源利用。
要点
- 在脓毒症/脓毒性休克合并3期AKI成人中,仅8.6%在入院≤24小时内接受白蛋白。
- 早期白蛋白组中位出院时间13.2天 vs 非早期组17.0天(Log-rank p<0.0001)。
- 校正分析:早期白蛋白组临床稳定出院率较非早期组提高83%(HR 1.832,95%CI 1.564-2.146,p<0.001)。
- 作者认为早期白蛋白可能与更短的出院时间和更高的临床稳定出院率相关,提示改善医疗资源利用。
适用人群与场景
- 2013年1月至2018年4月住院、诊断为脓毒症/脓毒性休克(ICD-9和ICD-10编码识别)并住院期间发生3期急性肾损伤(KDIGO标准)的成人患者(n=2,829,共2,845次唯一住院记录)。
诊断标准与关键阈值
- 重度急性肾损伤定义为住院期间发生3期急性肾损伤(依据KDIGO标准)。
- 早期白蛋白定义为入院≤24小时内使用白蛋白;非早期白蛋白定义为未暴露或延迟暴露。
研究设计与关键结果
- 研究设计:回顾性队列研究,使用Cerner Health Facts国家数据库的去标识电子健康记录。
- 人群与样本量:脓毒症/脓毒性休克合并3期AKI成人患者n=2,829(2,845次唯一住院记录),2013年1月至2018年4月住院。
- 暴露分组:早期白蛋白(入院≤24小时内)占8.6%,非早期白蛋白(未暴露或延迟暴露)占其余。
- 主要结局:早期白蛋白组中位出院时间13.2天 vs 非早期组17.0天(Log-rank p<0.0001)。
- 校正分析:早期白蛋白组临床稳定出院率较非早期组提高83%(HR 1.832,95%CI 1.564-2.146,p<0.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,入院24小时内使用白蛋白与更短的出院时间和更高的临床稳定出院率相关,提示可能改善脓毒症/脓毒性休克合并3期AKI患者的医疗资源利用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Adults hospitalized with sepsis/septic shock commonly develop acute kidney injury (AKI) which imposes a significant burden on the healthcare system. The administration of early human albumin in this patient population may yield more efficient healthcare resource utilization.
OBJECTIVES: To examine the association between early use of albumin and time to discharge in adults who develop severe AKI while hospitalized with sepsis/septic shock.
DESIGN: Retrospective cohort study using de-identified electronic health records from a national database (Cerner Health Facts; Cerner Corp., Kansas City, MO).
SETTING AND PARTICIPANTS: Patients (n = 2,829) hospitalized between January 2013 and April 2018 with a diagnosis of sepsis/septic shock (identified using International Classification of Diseases, 9th Revision and 10th Revision codes) who developed severe AKI (stage 3 according to Kidney Disease Improving Global Outcomes criteria) during hospitalization (n = 2,845 unique encounters).
MAIN OUTCOMES AND MEASURES: Patients were grouped according to timing of albumin exposure: within less than or equal to 24 hours of admission ("early albumin") or unexposed/exposed late ("nonearly albumin"). A cause-specific hazard model, censoring for death/discharge to hospice, was used to examine the association between "early albumin" and the rate of hospital discharge with clinical stability.
RESULTS: Albumin was administered early in 8.6% of cases. Cases with early albumin administration had a median time to discharge of 13.2 days compared with 17.0 in the nonearly group (Log-rank p < 0.0001). An adjusted analysis showed that the rate of hospital discharge with clinical stability increased by 83% in the early albumin group compared with the nonearly group (hazard ratio, 1.832; 95% CI, 1.564-2.146; p < 0.001 nonearly group.
CONCLUSIONS AND RELEVANCE: The use of albumin within 24 hours of hospital admission was associated with a shorter time to discharge and a higher rate of discharge with clinical stability, suggesting an improvement in healthcare resource utilization among patients with sepsis/septic shock who developed stage 3 AKI during hospitalization.
参考来源
- Raghunathan K, Kempker JA, Davis EA, et al. Early Albumin Infusion Is Associated With Greater Survival to Discharge Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury Among Patients With Sepsis/Septic Shock Who Develop Severe Acute Kidney Injury. Crit Care Explor. 2022. PMID: 36583206. doi:10.1097/CCE.0000000000000793
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。